- This Season: Everybody's A Scrooge
- Warren Buffett, Bill Gates 'Walk & Talk' At Columbia
- Senate Democrats at Odds Over Health Care Bill
- What if a Recovery Is All in Your Head?
- Thanksgiving Week Stuffed With Economic News
- A Taxpayer's Must Read: The Fed Waltz With AIG
- Newspaper Circulation May Be Worse Than it Looks
- 10 Tips to Get Out of Debt
- Investors to Goldman: Be Less Greedy
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Report: Ill. prison deal could create 3,000 jobs
- Proposal to merge black schools draws fire
- Promoters have faith in ‘holy hip-hop’
- Real estate agents see return of foreign buyers
- Newspaper circulation may be worse than it looks
- Accounting rule helps boost some newspapers
- Holidays will again test NYC air travel bottleneck
- RI slow to spend millions in stimulus funding
- Rising unemployment taxes could hinder hiring
Mylan gets FDA approval for generic Prevacid
Text Size 
PITTSBURGH - Mylan Inc. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
Mylan will sell 15-milligram and 30-milligram delayed-release capsule versions of the drug.
Mylan said the branded version of Prevacid had sales of about $3 billion in the 12 months ending June 30.
Shares of Mylan fell 32 cents to $17.59 in afternoon trading.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Print
Email
- Technology can make or break a fortune in the world of alternative energy.
- Warren Buffett and Bill Gates discusses the economy and other subjects with CNBC's Becky Quick.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes